Transfer of Her-2/neu specificity into cytokine-induced killer (CIK) cells with RNA encoding chimeric immune receptor (CIR)

J Clin Immunol. 2009 Nov;29(6):806-14. doi: 10.1007/s10875-009-9308-6. Epub 2009 Jun 11.

Abstract

Background: Efficient RNA transfer to dendritic cell and T cells by electroporation have been successfully applied for immunotherapy. Herein, RNA electroporation was used to transfer antigen-specific receptor (scFv) gene to cytokine-induced killer cells (CIK).

Methods: CIK was generated from peripheral blood mononuclear cells with anti-CD3 antibody, interleukin-2, and interferon (IFN)-gamma for 14 days and showed typical characteristics of CIK expressing both CD3+ and CD56+ markers and NKG2D+. CIK could lyse K562 cells, but not SKOV3 and MCF7/Her-2/neu.

Results: After RNA encoding anti-Her-2/neu chimeric immune receptor (CIR) with signaling portion of CD28 and CD3zeta was electroporated to CIK, more than 95% of CIK expressed anti-Her-2/neu CIR (CIR-CIK). CIR-CIK was able to produce cytokines including IFN-gamma, granulocyte-macrophage colony-stimulating factor, and tumor necrosis factor-alpha, and show cytotoxicity specific to tumor cell lines expressing Her-2/neu, SKOV3, and MCF7/Her-2/neu. Adoptive transfer of CIR-CIK in SKOV3 xenograft nude mice model led to significant inhibition of tumor growth compared with transfer of mock-transduced CIK and showed higher inhibition than that of Herceptin, humanized monoclonal antibody specific for Her-2/neu. These results suggest that RNA transfer is the convenient and efficient strategy to introduce antigen-specificity into CIK and provide potential therapeutic value of CIR-CIK in the treatment of tumors.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adoptive Transfer
  • Animals
  • Cell Culture Techniques
  • Cell Line, Tumor
  • Cells, Cultured
  • Cytokine-Induced Killer Cells / immunology
  • Cytokine-Induced Killer Cells / metabolism*
  • Cytotoxicity, Immunologic*
  • Electroporation
  • Humans
  • Mice
  • Mice, Nude
  • Neoplasms, Experimental / therapy*
  • RNA / administration & dosage*
  • RNA / therapeutic use
  • Receptor, ErbB-2 / immunology*
  • Single-Chain Antibodies / genetics*
  • Transplantation, Heterologous
  • Treatment Outcome

Substances

  • Single-Chain Antibodies
  • RNA
  • ERBB2 protein, human
  • Receptor, ErbB-2